Krishnansu S Tewari

Krishnansu S Tewari

UNVERIFIED PROFILE

Are you Krishnansu S Tewari?   Register this Author

Register author
Krishnansu S Tewari

Krishnansu S Tewari

Publications by authors named "Krishnansu S Tewari"

Are you Krishnansu S Tewari?   Register this Author

100Publications

1293Reads

11Profile Views

Bevacizumab in Cervical Cancer: 5 Years After.

Cancer J 2018 Jul/Aug;24(4):187-192

From the University of California Irvine Medical Center, Orange, CA.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00130404-201807000-0000
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000324DOI Listing
June 2019

Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.

J Clin Oncol 2019 Jun 26;37(17):1449-1454. Epub 2019 Apr 26.

1 University of California Irvine, Orange, CA.

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/JCO.19.00119
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00119DOI Listing
June 2019

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

N Engl J Med 2019 06;380(24):2317-2326

From Northwestern University (D. Matei) and Loyola University (W.S.) - both in Chicago; NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY (V.F., H.Q.H.); University of Kentucky, Lexington (M.E.R.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (D. Mutch, M.A.P.); Women and Infants Hospital in Rhode Island-The Warren Alpert Medical School of Brown University, Providence (M.M.S., P.A.D.); Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City (K.M.M.); Asan Medical Center, University of Ulsan, Songpa-gu, Seoul, South Korea (Y.M.K.); Ohio State University, Columbus (D.M.O.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); University of California Irvine Medical Center, Irvine (K.S.T.); Lewis Cancer and Research Pavilion at St. Joseph's-Candler, Savannah, GA (W.E.R.); Case Western Reserve University Hospital, Cleveland (J.N.); Dana-Farber Cancer Institute, Boston (U.A.M.); and the University of Texas Southwestern Medical Center, Dallas (D.S.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1813181DOI Listing
June 2019

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Obstet Gynecol 2019 Feb;133(2):245-254

Cleveland Clinic Foundation and Case Western Reserve University, Cleveland, Ohio; NRG Oncology Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, New York; The Ohio State University, Columbus, Ohio; the University of Minnesota, Minneapolis, Minnesota; Duke University Hospital; Durham, North Carolina; the University of California at Irvine, Orange, California; the University of Iowa Hospital, Iowa City, Iowa; Washington University in St. Louis School of Medicine, St. Louis, Missouri; ANZGOG, Australia-New Zealand Gynaecological Oncology Group, Sydney, Australia; the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Community Health Network and Indiana University School of Medicine, Indianapolis, Indiana; Walter Reed Army Medical Center; Bethesda, Maryland; Tacoma General Hospital, Tacoma, Washington; Moffitt Cancer Center, Tampa, Florida; the University of Colorado School of Medicine at Denver, Aurora, Colorado; Cancer Treatment Centers of America, Philadelphia Pennsylvania; NYU Clinical Cancer Center, New York, New York; Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland; US Oncology Research, Arizona Oncology, Tucson, Arizona; the University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; and The Ohio State University Medical Center, Columbus, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0000000000003086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551603PMC
February 2019

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations.

Drugs Context 2018 27;7:212558. Epub 2018 Dec 27.

University of California Irvine Medical Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7573/dic.212558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310180PMC
December 2018

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.

Ther Clin Risk Manag 2018 2;14:2189-2201. Epub 2018 Nov 2.

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange, CA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/TCRM.S149248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223341PMC
November 2018

The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.

Recent Pat Biotechnol 2018 ;12(2):101-112

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine-Medical Center, Orange, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1872208311666171122152131DOI Listing
October 2018

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.

J Clin Oncol 2018 Oct 5:JCO1800454. Epub 2018 Oct 5.

Martee L. Hensley, Memorial Sloan Kettering Cancer Center; Martee L. Hensley and Oliver Zivanovic, Weill Cornell Medical College, New York City; Danielle Enserro and Shashikant B. Lele, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Helen Hatcher, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge; Cyril Fisher, University of Birmingham, Birmingham, United Kingdom; Petronella B. Ottevanger, Radboud University Medical Center, Nijmegen, the Netherlands; Anders Krarup-Hansen, University Hospital Copenhagen, Copenhagen, Denmark; Jean-Yves Blay, Centre Leon Berard, Lyon, France; Katherine M. Moxley, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Jayanthi S. Lea, and David S. Miller, The University of Texas Southwestern Medical Center, Dallas, TX; Krishnansu S. Tewari, University of California at Irvine, Orange, CA; Premal H. Thaker, Washington University School of Medicine, and Siteman Cancer Center, St Louis, MO; David M. O'Malley, The Ohio State University College of Medicine, Columbus, OH; Katina Robison, Women and Infants Hospital in Rhode Island, Providence, RI.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00454
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241678PMC
October 2018

Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer.

Expert Opin Drug Discov 2018 05 26;13(5):445-457. Epub 2018 Feb 26.

a Division of Gynecologic Oncology , University of California, Irvine Medical Center , Orange , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1443074DOI Listing
May 2018

Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.

Expert Opin Drug Metab Toxicol 2018 May 16;14(5):543-550. Epub 2018 May 16.

a University of California , Irvine Medical Center , Orange , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2018.1461838DOI Listing
May 2018

Oncofertility in the setting of advanced cervical cancer - A case report.

Gynecol Oncol Rep 2018 May 2;24:27-29. Epub 2018 Mar 2.

Department of Obstetrics & Gynecology, University of California, Irvine 333 City Blvd, West, Suite 1400, Orange, CA 92868, United States.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525789183001
Publisher Site
http://dx.doi.org/10.1016/j.gore.2018.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966584PMC
May 2018

Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.

Gynecol Oncol 2018 03 3;148(3):609-621. Epub 2018 Feb 3.

The Division of Gynecologic Oncology, University of California, Irvine, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.01.009DOI Listing
March 2018

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.

Br J Cancer 2018 01 28;118(2):162-170. Epub 2017 Nov 28.

Department of Pathology (SL) and Department of Gynecologic Oncology (KT), Irvine Medical Center, University of California, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785748PMC
January 2018

Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.

Curr Pharm Des 2016 ;22(30):4717-4728

Dignity Health St. Joseph's Hospital and Medical Center, 500 W. Thomas Road, Suite 600, Phoenix, AZ 85013.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967614PMC
November 2017

Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology.

J Gynecol Oncol 2017 09;28(5):e74

Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3802/jgo.2017.28.e74DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540730PMC
September 2017

The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.

Expert Rev Anticancer Ther 2017 Mar 15;17(3):191-198. Epub 2017 Feb 15.

a The Division of Gynecologic Oncology, Department of Obstetrics & Gynecology , University of California, Irvine Medical Center , Orange , CA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737140.2016.1
Publisher Site
http://dx.doi.org/10.1080/14737140.2016.1246187DOI Listing
March 2017

Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.

Recent Pat Biotechnol 2016 ;9(2):86-101

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine-Medical Center, Orange CA 92868, USA.

View Article

Download full-text PDF

Source
December 2016

Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.

Expert Opin Drug Metab Toxicol 2016 Oct 16;12(10):1247-53. Epub 2016 Aug 16.

a University of California , Irvine Medical Center , Orange , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2016.1216976DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613934PMC
October 2016

Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies.

Gynecol Oncol Res Pract 2016 24;3:10. Epub 2016 Oct 24.

The Division of Gynecologic Oncology, University of California, Irvine Medical Center, The City Tower, 333 City Blvd W., Orange, CA 92868 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40661-016-0031-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078960PMC
October 2016

A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE.

Future Oncol 2015 24;11(23):3113-31. Epub 2015 Nov 24.

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine-Medical Center, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.266DOI Listing
September 2016

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

J Clin Oncol 2016 07 23;34(19):2279-86. Epub 2016 May 23.

Bradley J. Monk, University of Arizona Cancer Center at Dignity Health St Joseph's Hospital and Medical Center, Phoenix, AZ; Michael W. Sill, Roswell Park Cancer Institute, Buffalo; Carol Aghajanian, Memorial Sloan Kettering Cancer Center, New York, NY; Joan L. Walker, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Christopher J. Darus, Maine Medical Center, Portland, ME; Gregory Sutton, Washington University School of Medicine, St. Louis, MO; Krishnansu S. Tewari, University of California Irvine Medical Center, Orange; Jai Balkissoon, Pharmaceutical Product Development International, South San Francisco, CA; Lainie P. Martin, Fox Chase Cancer Center, Philadelphia, PA; Jeanne M. Schilder, Indiana University Medical Center, Indianapolis, IN; and Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.8153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962710PMC
July 2016

Updates on drug discovery in ovarian cancer.

Gynecol Oncol Res Pract 2014 30;1. Epub 2014 Sep 30.

The Division of Gynecologic Oncology, University of Arizona Cancer Center, 500 West Thomas Road, Suite 600, Phoenix, AZ 85013 USA ; Creighton University School of Medicine, St. Joseph's Hospital and Medical Center, A Dignity Health Member, 500 West Thomas Road, Suite 600, Phoenix, AZ 85013 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2053-6844-1-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878024PMC
May 2016

Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.

Oncologist 2016 05 29;21(5):576-85. Epub 2016 Mar 29.

University of California, Irvine, Orange, California, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0393DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861362PMC
May 2016

US FDA oncology drug approvals in 2014.

Future Oncol 2015 22;11(13):1931-45. Epub 2015 May 22.

The Chao Family NCI-Designated Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive South, Bldg 56, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.106DOI Listing
April 2016

New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.

Curr Treat Options Oncol 2016 Mar;17(3):12

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, 101 The City Drive, Buliding 56, Orange, CA, 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0378-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927601PMC
March 2016

Changing paradigms in the systemic treatment of advanced cervical cancer.

Am J Obstet Gynecol 2016 Jan 26;214(1):22-30. Epub 2015 Jul 26.

Division of Gynecologic Oncology, University of California, Irvine, Orange, CA; Division of Gynecologic Oncology, University of California, Irvine, Irvine Medical Center, University of California, Orange, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2015.07.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613936PMC
January 2016

Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

Future Oncol 2015 ;11(6):909-22

Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.276DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613942PMC
November 2015

Clinical implications for cediranib in advanced cervical cancer.

Lancet Oncol 2015 Nov 22;16(15):1447-1448. Epub 2015 Oct 22.

The Division of Gynecologic Oncology, University of California, Irvine, CA 92660, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00252-1DOI Listing
November 2015

Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Drugs 2015 Nov;75(16):1853-65

University of California, Irvine Medical Center, 101 The City Drive South, Bldg 56, Orange, CA, 92868, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061500PMC
http://dx.doi.org/10.1007/s40265-015-0481-zDOI Listing
November 2015

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.

Clin Cancer Res 2015 Sep 13;21(17):3829-35. Epub 2015 Jul 13.

The Division of Gynecologic Oncology, University of Arizona Cancer Center at Dignity Health St. Joseph's Hospital and Medical Center, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0088DOI Listing
September 2015

A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.

Gynecol Oncol 2015 Jun 10;137(3):490-6. Epub 2015 Mar 10.

The Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.02.027DOI Listing
June 2015

Anti-angiogenesis therapy in gynecologic malignancies.

Oncology (Williston Park) 2015 May;29(5):350-60

View Article

Download full-text PDF

Source
May 2015

Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.

Am J Obstet Gynecol 2015 Apr 31;212(4):468.e1-9. Epub 2014 Oct 31.

Division of Gynecologic Oncology, Irvine Medical Center, University of California, Orange, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2014.10.1104DOI Listing
April 2015

Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.

Expert Opin Pharmacother 2015 Apr 3;16(5):675-83. Epub 2015 Feb 3.

University of California Irvine Medical Center , Orange, CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2015.1010511DOI Listing
April 2015

Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome.

Gynecol Oncol Rep 2015 Apr 26;12:31-3. Epub 2015 Feb 26.

Division of Gynecologic Oncology, The Chao Family NCI-Designated Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA ; Gynecologic Oncology Program, The Center for Cancer Prevention and Treatment, St. Joseph Hospital, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2015.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442652PMC
April 2015

Reply to W.A.A. Tjalma and J.S. Grossman.

J Clin Oncol 2015 Mar 9;33(8):966. Epub 2015 Feb 9.

Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.6205DOI Listing
March 2015

Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer.

Clin Ther 2015 Jan;37(1):9-19

The Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2014.11.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581982PMC
January 2015

Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.

Clin Ther 2015 Jan;37(1):20-38

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2014.11.010DOI Listing
January 2015

New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.

Clin Cancer Res 2014 Nov 7;20(21):5349-58. Epub 2014 Aug 7.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arizona Cancer Center, Creighton University School of Medicine at Dignity Health St. Joseph's Hospital and Medical Center, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1099DOI Listing
November 2014

Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.

Expert Rev Clin Pharmacol 2014 Nov 10;7(6):847-58. Epub 2014 Oct 10.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California Irvine Medical Center, Building 56 Room 260, 101 The City Drive South, Orange CA 92868 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2014.968554DOI Listing
November 2014

Targeting angiogenesis in advanced cervical cancer.

Ther Adv Med Oncol 2014 Nov;6(6):280-92

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, 101 The City Dr. South, Building 56 Room 264, 101 The City Dr., Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834014543794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206649PMC
November 2014

Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer.

Clin Adv Hematol Oncol 2014 Nov;12(11):737-48

University of Arizona Cancer Center, Phoenix, AZ.

View Article

Download full-text PDF

Source
November 2014

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

J Clin Oncol 2014 Oct 8;32(29):3275-83. Epub 2014 Sep 8.

Mark E. Sherman, Phuong L. Mai, Lori Minasian, and Mark H. Greene, National Cancer Institute, Rockville; Olga B. Ioffe, University of Maryland Medical Center; Brigitte M. Ronnett, Johns Hopkins Medical Institutions, Baltimore; Chad A. Hamilton, Walter Reed National Military Medical Center, Bethesda, MD; Marion Piedmonte, Roswell Park Cancer Institute, Buffalo; Stephanie V. Blank, New York University School of Medicine; Noah D. Kauff, Memorial Sloan Kettering Cancer Center; New York, NY; Linda Van Le, University of North Carolina at Chapel Hill, Chapel Hill, NC; Iouri Ivanov, Columbus Cancer Council, Columbus, OH; Maria C. Bell, Sanford University of South Dakota Medical Center, Sioux Falls, SD; Paul DiSilvestro, Women and Infants Hospital, Providence, RI; Krishnansu S. Tewari, University of California Medical Center Irvine, Orange, CA; Katie Wakeley, Tufts University; Steven J. Skates, Massachusetts General Hospital, Boston, MA; S. Diane Yamada, University of Chicago, Chicago; Gustavo Rodriguez, North Shore University Health System, Evanston, IL; David S. Alberts, University of Arizona Cancer Center, Tucson, AZ; Joan L. Walker, University of Oklahoma, Oklahoma City, OK; and Karen Lu, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.1987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178524PMC
October 2014

PARP inhibition and synthetic lethality in ovarian cancer.

Expert Rev Clin Pharmacol 2014 Sep 2;7(5):613-22. Epub 2014 Jul 2.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California Irvine Medical Center, Building 56 Room 260, 101 The City Dr., Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2014.930662DOI Listing
September 2014

Evidence-based therapy for recurrent cervical cancer.

J Clin Oncol 2014 Sep 28;32(25):2687-90. Epub 2014 Jul 28.

University of California Irvine Medical Center, Orange, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.8733DOI Listing
September 2014

Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.

J Clin Oncol 2014 Sep 28;32(25):2744-9. Epub 2014 Jul 28.

David Scott Miller, University of Texas Southwestern Medical Center, Dallas; Lois M. Ramondetta and Jubilee Brown, MD Anderson Cancer Center, Houston, TX; John A. Blessing, Roswell Park Cancer Institute, Buffalo, NY; Huyen Q. Pham, University of Southern California, Los Angeles; Krishnansu S. Tewari, University of California Medical Center at Irvine, Orange, CA; and Lisa M. Landrum and Robert S. Mannel, University of Oklahoma, Oklahoma City, OK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.7448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145184PMC
September 2014

Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.

Curr Opin Obstet Gynecol 2014 Aug;26(4):314-21

Irvine Medical Center, University of California, Orange, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GCO.0000000000000042DOI Listing
August 2014

Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.

J Gynecol Oncol 2014 Jul 3;25(3):249-59. Epub 2014 Jul 3.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3802/jgo.2014.25.3.249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102744PMC
July 2014

Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.

Gynecol Oncol 2014 Jun 20;133(3):439-45. Epub 2014 Mar 20.

Dept. of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Arizona Cancer Center, Creighton University School of Medicine, St. Joseph's Hospital & Medical Center, Phoenix, AZ 85013, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2014.03.013DOI Listing
June 2014

Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review.

World J Radiol 2014 Jun;6(6):366-73

Beverly Long, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, CA 92868, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4329/wjr.v6.i6.366DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072821PMC
June 2014

New world order(s): healthcare metrics, international borders, and gravitational waves.

Gynecol Oncol 2014 May;133(2):139-41

The Division of Gynecologic Oncology, University of California, Irvine, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258140081
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2014.04.001DOI Listing
May 2014

Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.

Gynecol Oncol 2014 Feb 3;132(2):496-505. Epub 2013 Dec 3.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Building 56, 101 The City Dr., Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.11.029DOI Listing
February 2014

Improved survival with bevacizumab in advanced cervical cancer.

N Engl J Med 2014 Feb;370(8):734-43

From the University of California, Irvine, Medical Center, Orange (K.S.T.); Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo (M.W.S., H.H.); Mayo Clinic, Rochester, MN (H.J.L.); Massachusetts General Hospital, Boston (R.T.P.); M.D. Anderson Cancer Center, Houston (L.M.R.); University of Oklahoma, Oklahoma City (L.M.L.); Vall d'Hebron University Hospital, Barcelona (A.O.); University of Cincinnati College of Medicine-Women's Cancer Center at Kettering, Kettering, OH (T.J.R.); Memorial Sloan-Kettering Cancer Center, New York (M.M.L.); Indiana University School of Medicine, Indianapolis (H.E.M.); and the University of Arizona Cancer Center and Creighton University at St. Joseph's Hospital and Medical Center, Phoenix (B.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1309748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094PMC
February 2014

American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer.

Int J Gynecol Cancer 2014 Jan;24(1):13-8

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Orange, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907666PMC
January 2014

Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass.

Am J Obstet Gynecol 2013 Dec 11;209(6):581.e1-8. Epub 2013 Aug 11.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Medical Center, Orange, CA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00029378130083
Publisher Site
http://dx.doi.org/10.1016/j.ajog.2013.08.009DOI Listing
December 2013

Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.

Clin Pharmacol 2013 Oct 3;5(Suppl 1):55-61. Epub 2013 Oct 3.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CPAA.S45885DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795053PMC
October 2013

Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma.

Clin Pharmacol 2013 23;5:13-9. Epub 2013 May 23.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CPAA.S40401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666910PMC
June 2013

Outside slide review in gynecologic oncology: impact on patient care and treatment.

Int J Gynecol Pathol 2013 May;32(3):293-8

Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0b013e31826739c4DOI Listing
May 2013

Advanced cytoreductive surgery workshop report.

Int J Gynecol Cancer 2012 Nov;22(9):1604-10

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California-Irvine Medical Center, 101 The City Drive South, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00009577-201211000-000
Publisher Site
http://dx.doi.org/10.1097/IGC.0b013e3182738338DOI Listing
November 2012

American Society of Clinical Oncology 2012 Annual Meeting: highlights from the gynecologic oncology track.

Int J Gynecol Cancer 2012 Nov;22(9):1634-9

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California-Irvine Medical Center, 101 The City Drive South, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0b013e318270febeDOI Listing
November 2012

Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

Int J Womens Health 2012 3;4:395-404. Epub 2012 Aug 3.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California at Irvine, Irvine, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJWH.S29467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422105PMC
October 2012

Role of canonical Wnt signaling in endometrial carcinogenesis.

Expert Rev Anticancer Ther 2012 Jan;12(1):51-62

Divison of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, Medical Center, 101 The City Drive, Building 56, Room 260, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.11.194DOI Listing
January 2012

Fertility preserving options in patients with gynecologic malignancies.

Am J Obstet Gynecol 2011 Aug 16;205(2):103-10. Epub 2011 Mar 16.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2011.01.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111967PMC
August 2011

American Society of Clinical Oncology 2011 Annual Meeting update: summary of selected gynecologic cancer abstracts.

Gynecol Oncol 2011 Aug;122(2):209-12

The Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2011.06.028DOI Listing
August 2011

Drug discovery in ovarian cancer.

Recent Pat Anticancer Drug Discov 2010 Nov;5(3):251-60

The Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, The Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, 92868, USA.

View Article

Download full-text PDF

Source
November 2010

Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: a pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression.

J Med Virol 2010 Feb;82(2):311-20

Department of Molecular Biology and Biochemistry, University of California at Irvine, Irvine, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.21676DOI Listing
February 2010

Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma.

Gynecol Oncol 2009 Dec 22;115(3):339-42. Epub 2009 Sep 22.

Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2009.08.008DOI Listing
December 2009

Beyond platinum for metastatic and recurrent carcinoma of the cervix.

Onkologie 2009 Oct 15;32(10):552-4. Epub 2009 Sep 15.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000232385DOI Listing
October 2009

Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience.

Int J Gynecol Cancer 2009 Aug;19(6):1080-4

Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California-Irvine, 101 The City Drive, Orange, CA 92868-3298, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/IGC.0b013e3181acae50DOI Listing
August 2009

Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.

Semin Oncol 2009 Apr;36(2):170-80

Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine-Medical Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2008.12.008DOI Listing
April 2009

Green tea catechins for treatment of external genital warts.

Am J Obstet Gynecol 2009 Mar 18;200(3):233.e1-7. Epub 2008 Nov 18.

Department of Obstetrics and Gynecology, University of California, Irvine, Medical Center, Orange, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2008.07.064DOI Listing
March 2009

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

Gynecol Oncol 2009 Jan 1;112(1):85-9. Epub 2008 Nov 1.

Department of OB/GYN, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2008.09.029DOI Listing
January 2009

The influence of conservative surgical practices for malignant ovarian germ cell tumors.

J Surg Oncol 2008 Aug;98(2):111-6

Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco School of Medicine, UCSF Helen Diller Family, Comprehensive Cancer Center, San Francisco, California 94143-1702, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.21079DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111627PMC
August 2008

Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease.

Am J Obstet Gynecol 2008 Jul;199(1):3-9

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Irvine, CA 92868, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S000293780800401
Publisher Site
http://dx.doi.org/10.1016/j.ajog.2008.04.010DOI Listing
July 2008